TD Asset Management Inc Grows Stock Holdings in Vera Therapeutics, Inc. $VERA

TD Asset Management Inc grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 54.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 325,564 shares of the company’s stock after purchasing an additional 115,090 shares during the period. TD Asset Management Inc owned approximately 0.51% of Vera Therapeutics worth $16,487,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in VERA. Vestal Point Capital LP lifted its holdings in shares of Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares during the last quarter. Integral Health Asset Management LLC lifted its holdings in shares of Vera Therapeutics by 47.8% during the third quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock valued at $49,402,000 after purchasing an additional 550,000 shares during the last quarter. Braidwell LP purchased a new position in shares of Vera Therapeutics during the third quarter valued at approximately $13,738,000. Armistice Capital LLC lifted its holdings in shares of Vera Therapeutics by 294.1% during the third quarter. Armistice Capital LLC now owns 536,000 shares of the company’s stock valued at $15,576,000 after purchasing an additional 400,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Vera Therapeutics by 11.9% during the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock valued at $180,805,000 after purchasing an additional 379,748 shares during the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

VERA has been the subject of several recent research reports. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. The Goldman Sachs Group reiterated a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Finally, HC Wainwright boosted their price objective on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Vera Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $78.00.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA opened at $31.75 on Tuesday. Vera Therapeutics, Inc. has a twelve month low of $19.07 and a twelve month high of $56.05. The firm has a market cap of $2.28 billion, a P/E ratio of -5.73 and a beta of 0.93. The company has a 50 day moving average of $37.54 and a 200 day moving average of $41.35. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter last year, the firm posted ($0.81) EPS. As a group, research analysts expect that Vera Therapeutics, Inc. will post -6.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $36.74, for a total transaction of $679,690.00. Following the completion of the sale, the chief executive officer directly owned 216,744 shares in the company, valued at approximately $7,963,174.56. The trade was a 7.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.